Dyslipidemia has been associated with type 2 diabetes ([@B1]), and the most common patterns of dyslipidemia in diabetic patients are reduced HDL cholesterol and elevated triglyceride levels. Prospective studies also have shown that low HDL cholesterol and high triglyceride levels, but not LDL cholesterol levels, are independent risk factors for type 2 diabetes ([@B2]--[@B7]), and the values of HDL cholesterol and/or triglycerides have been used in the risk-scoring systems for predicting incident diabetes ([@B4],[@B6],[@B7]). However, it remains unclear whether low HDL cholesterol/high triglyceride levels play a causal role in the development of type 2 diabetes.

Information on the associations of genetic predisposition to dyslipidemia with risk of type 2 diabetes might help clarify the causality. A recent study reported that a genotype score for triglyceride levels was not associated with type 2 diabetes risk ([@B8]). However, the less extensive inclusion of the susceptibility loci (nine loci) might limit the causal inference. Moreover, the study did not address other patterns of dyslipidemia (high LDL cholesterol and low HDL cholesterol levels).

Recently, a meta-analysis of 46 lipid genome-wide association studies comprising \>100,000 individuals of European ancestry has established more comprehensive genetic profiles for various blood lipids, including LDL cholesterol, HDL cholesterol, and triglycerides ([@B9]). In the current study, we calculated three genotype scores on the basis of 31, 41, and 25 well-established single nucleotide polymorphisms (SNPs) for LDL cholesterol, HDL cholesterol, and triglycerides, respectively, as proxies of genetic predisposition to dyslipidemia. We examined the effects of these dyslipidemia genotype scores on type 2 diabetes risk in women and men of European ancestry from two prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS).

RESEARCH DESIGH AND METHODS {#s2}
===========================

The NHS is a prospective cohort study of 121,700 female registered nurses who were aged 30--55 years at study inception in 1976 when all of them completed a mailed questionnaire on their medical history and lifestyle ([@B10]). A total of 32,826 women provided blood samples between 1989 and 1990. The HPFS is a prospective cohort study of 51,529 U.S. male health professionals who were aged 40--75 years at study inception in 1986 ([@B11]). Between 1993 and 1999, 18,159 men provided blood samples. In both cohorts, information about health and disease has been collected biennially by self-administered questionnaires every 2 years since inception. The study was approved by the human research committee at the Brigham and Women's Hospital (Boston, MA), and all participants provided written informed consent.

Participants for the current study were selected among those with a blood sample using a nested case-control study design ([@B12],[@B13]). Diabetes cases were defined as self-reported diabetes confirmed by a validated supplementary questionnaire ([@B14],[@B15]). For cases before 1998, we used the National Diabetes Data Group criteria to define diabetes ([@B16]), which included one of the following: one or more classic symptoms (excessive thirst, polyuria, weight loss, hunger, pruritus, or coma) plus a fasting plasma glucose level of ≥7.8 mmol/L (140 mg/dL), a random plasma glucose level of ≥11.1 mmol/L (200 mg/dL), or a plasma glucose level 2 h after an oral glucose tolerance test of ≥11.1 mmol/L (200 mg/dL); at least two elevated plasma glucose levels (as described previously) on different occasions in the absence of symptoms; or treatment with hypoglycemia medication (insulin or oral hypoglycemic agent). We used the American Diabetes Association diagnostic criteria for diabetes diagnosis from 1998 onward ([@B17]). These criteria were the same as those proposed by the National Diabetes Data Group, except for the elevated fasting plasma glucose criterion, for which the cut point was changed from 7.8 mmol/L (140 mg/dL) to 7.0 mmol/L (126 mg/dL). Only case subjects with diagnosed diabetes after the cohort baseline were included. Control subjects were defined as those free of diabetes at the time of the diagnosis of case and remained unaffected through follow-up (2006). After applying a quality-control filter in the NHS and HPFS T2D GWA scans ([@B13]), duplicate samples, samples with misidentified sex, related samples (siblings or possible first cousins), samples with evidence of contamination, samples with highly variable intensity data, and samples with missing call rates ≥2% were excluded. Population structure was investigated by principal component analysis ([@B18]). In this analysis, participants clustered with the HapMap CEU samples were genetically inferred to have European ancestry. Finally, a total of 3,088 (1,334 case and 1,754 control subjects) women and 2,411 (1,113 case and 1,298 control subjects) men of genetically inferred European ancestry were included in the current analysis.

Assessment of plasma lipids and covariates. {#s3}
-------------------------------------------

Plasma lipid levels were measured in 718 women and 753 men with type 2 diabetes (after the onset of diabetes). LDL cholesterol concentration was measured by a homogenous direct method from Genzyme (Cambridge, MA), with coefficients of variation of \<3.1%. Concentrations of triglycerides and HDL cholesterol were measured simultaneously on the Hitachi 911 analyzer using reagents and calibrators from Roche Diagnostics (Indianapolis, IN), with coefficients of variation of \<1.8%.

Information about anthropometric data, lifestyle factors, menopausal status and postmenopausal hormone therapy (women only), and medication use was derived from the baseline questionnaires ([@B10],[@B11]). BMI was calculated as weight in kilograms divided by the square of height in meters. For men, physical activity was expressed as metabolic equivalents per week by using the reported time spent on various activities, weighting each activity by its intensity level. For women, physical activity was expressed as hours per week because metabolic equivalent task hours were not measured at baseline in the NHS. The validity of the self-reported body weight and physical activity data have been described previously ([@B19]--[@B21]).

Genotyping. {#s4}
-----------

SNPs genotyping and imputation have been described in detail elsewhere (the NHS and HPFS T2D GWA scans) ([@B13]). In brief, samples were genotyped and analyzed using the Affymetrix Genome-Wide Human 6.0 array (Santa Clara, CA) and the Birdseed calling algorithm. All samples used in the current study achieved a call rate of \>98%. Individual SNPs were excluded if they were monomorphic, had a missing call rate of ≥2%, had more than one discordance in the multiple genotyped samples (one HapMap control sample was genotyped 12 times), or had a Hardy-Weinberg equilibrium *P* value of \<1 × 10^−4^ or a minor allele frequency of \<0.02. We used MACH (<http://www.sph.umich.edu/csg/abecasis/mach>) to impute SNPs on chromosomes 1--22, with National Center for Biotechnology Information build 36 of phase II HapMap CEU data (release 22) as the reference panel.

Genotype score calculation. {#s5}
---------------------------

To estimate the genetic predisposition to dyslipidemia, three lipid (LDL cholesterol, HDL cholesterol, and triglycerides) genotype scores were calculated on the basis of the well-established SNPs in 95 loci for blood lipids reported by a recent meta-analysis of genome-wide association studies ([@B9]). Only SNPs with genotyped data or high imputation quality scores (MACH *r*^2^ ≥ 0.8) were included. To minimize the influence of pleotropic effects, the SNPs or their correlated SNPs (*r*^2^ ≥ 0.80), which have been reported to be associated with type 2 diabetes risk or fasting glucose at a genome-wide significance level, including the SNPs in *GCKR* ([@B22]), *FADS1* ([@B22]), *IRS1* ([@B23]), and *KLF14* ([@B24]) loci, were excluded, leaving 31, 41, and 25 SNPs for LDL cholesterol, HDL cholesterol, and triglycerides, respectively, in the current analysis ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1254/-/DC1)). We assumed that each SNP in the panel acts independently in an additive manner, and the genotype scores were calculated by using a weighted method. Each SNP was weighted by its relative effect size (β-coefficient) obtained from the reported meta-analysis data ([@B9]). The genotype scores were calculated by multiplying each β-coefficient by the number of corresponding risk alleles and then summing the products. Because this produced an LDL cholesterol genotype score out of 115.88 (twice the sum of the β-coefficients), an HDL cholesterol genotype score out of 59.46 (twice the sum of the β-coefficients), and a triglyceride genotype score out of 247.36 (twice the sum of the β-coefficients), the values were divided by 115.88, 59.46, and 247.36 and multiplied by 62, 82, and 50 (the total number of the risk alleles), respectively, to make the genotype scores easier to interpret. In sensitivity analysis, four SNPs in *ANGPTL3*, *PPP1R3B*, *TRIB1*, and *APOA1--C3--A4--A5* loci for LDL cholesterol; five SNPs in *APOB*, *MLXIPL*, *TRIB*, *APOA1--C3--A4--A5*, and *LRP1* loci for HDL cholesterol; and four SNPs in *GALNT2*, *ZNF664*, *LIPC*, and *PLTP* loci for triglycerides were further excluded from the calculation of the respective genotype scores, because these SNPs had the largest effects on other two blood lipid traits ([@B9]).

Statistical analysis. {#s6}
---------------------

χ^2^ Tests and *t* tests were used for comparison of proportions and means between case patients and control participants. General linear regression models were applied to test the association between the plasma lipid levels and the respective genotypes scores in 673 women and 633 men with type 2 diabetes who were not taking lipid-lowering drugs. We used logistic regression to estimate odd ratios (ORs) for type 2 diabetes risk, adjusting for age and BMI. To examine the accumulative effects of the genotype scores, we compared the type 2 diabetes risk across the quartiles of the genotype scores. In multivariate analysis, we further adjusted for smoking (never, past, or current), alcohol intake (0, 0.1--4.9, 5.0--9.9, 10.0--14.9, or ≥15.0 g/day), menopausal status (pre- or postmenopausal \[never, past, or current hormone use\], women only), and physical activity (quintiles). Results in women and men were pooled by using inverse variance weights under a fixed model because there was no heterogeneity. Liner relation analysis between the genotype scores (as continuous variables) and risk of type 2 diabetes was performed by using a restricted cubic spline regression model ([@B25]). All reported *P* values are nominal and two sided. Statistical analyses were performed in SAS version 9.1 (SAS Institute, Cary, NC).

RESULTS {#s7}
=======

Characteristics of study participants. {#s8}
--------------------------------------

[Table 1](#T1){ref-type="table"} shows the baseline characteristics of participants of two nested case-control studies from the NHS (women) and HPFS (men). The patients were incident cases diagnosed during the follow-up through 2006 in these cohorts. Patients with type 2 diabetes had a significantly higher BMI, engaged in less physical activity, and were more likely to smoke and have a family history of diabetes than control subjects, among both women and men. In addition, among women, diabetic patients consumed less alcohol and were more likely to be postmenopausal than control subjects. In addition, the genotype scores were not associated with age, BMI, or lifestyle factors including smoking, alcohol intake, and physical activity (all *P* \> 0.05).

###### 

Characteristics of the participants at baseline
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Lipid genotype scores and plasma lipid levels. {#s9}
----------------------------------------------

[Figure 1](#F1){ref-type="fig"} presents the relationship between the three lipid genotype scores and the respective plasma lipid levels among diabetic women and men. The three genotype scores were all normally distributed among women and men. As expected, higher genotype scores were associated with higher plasma LDL cholesterol and triglyceride levels but lower HDL cholesterol levels, respectively, among both women and men (all *P* \< 0.0001).

![Lipid genotype scores and plasma lipids in diabetic women and men. *A*: LDL cholesterol (LDL-C). *B*: HDL cholesterol (HDL-C). *C*: Triglycerides. The histograms represent the percentage of participants, and the means ± SE of LDL cholesterol, HDL cholesterol, and triglycerides are plotted, with the trend lines across the respective genotype score, adjusted for age and BMI.](745fig1){#F1}

LDL cholesterol genotype score and type 2 diabetes. {#s10}
---------------------------------------------------

In women, the OR for type 2 diabetes was 1.01 (95% CI 0.98--1.03) with each point (corresponding to one unfavorable allele) of the LDL cholesterol genotype score, after adjustment for age and BMI ([Table 2](#T2){ref-type="table"}). In men, the corresponding OR for type 2 diabetes was 1.00 (0.98--1.03). Pooled results between women and men showed that the LDL cholesterol genotype score was not associated with type 2 diabetes (*P* for trend = 0.24). Linear relation analysis also indicated that there was no significant linear relationship between the LDL cholesterol genotype score and risk of type 2 diabetes ([Fig. 2*A*](#F2){ref-type="fig"}). In sensitivity analysis, we excluded four SNPs (*ANGPTL* rs3850634, *PPP1R3B* rs2126259, *TRIB1* rs2954022, and *APOA1--C3--A4--A5* rs964184) that had the largest effects on HDL cholesterol or triglyceride levels from the calculation of the LDL cholesterol genotype score, and we observed similar results (pooled OR 1.00 \[0.99--1.02\] with each point of the genotype score; *P* = 0.51).

###### 

Association between the LDL cholesterol genotype score and risk for type 2 diabetes
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![Spline plot of lipid genotype scores and risk for type 2 diabetes. *A*: LDL cholesterol (LDL-C) genotype score. *B*: HDL cholesterol (HDL-C) genotype score. C: Triglyceride genotype score. Data are ORs (solid lines) and 95% CIs (dashed lines), adjusted for age, sex, and BMI, for pooled data from women and men.](745fig2){#F2}

HDL cholesterol genotype score and type 2 diabetes. {#s11}
---------------------------------------------------

As shown in [Table 3](#T3){ref-type="table"}, the HDL cholesterol genotype score was significantly associated with an increased type 2 diabetes risk in women (OR 1.03 \[95% CI 1.01--1.05\] with each point of the genotype score). We observed a similar result in men (1.02 \[0.99--1.04\]), and the pooled OR for type 2 diabetes between women and men was 1.02 (1.01--1.04) with each point of the HDL cholesterol genotype score, adjusted for age and BMI. The ORs for type 2 diabetes increased across the quartiles of the HDL cholesterol genotype score (*P* for trend = 0.002). Compared with those in the lowest quartile of the HDL cholesterol genotype score, participants in the highest quartile had an OR of 1.37 (1.16--1.61). Multivariate adjustment did not change the associations. In addition, there was a linear relationship between the HDL cholesterol genotype score and increased risk of type 2 diabetes ([Fig. 2*B*](#F2){ref-type="fig"}). In sensitivity analysis, we excluded five SNPs (*APOB* rs1042034, *MLXIPL* rs17145738, *TRIB1* rs10808546, *APOA1--C3--A4--A5* rs964184, and *LRP1* rs11613352) that had the largest effects on LDL cholesterol or triglyceride levels from the calculation of the HDL cholesterol genotype score, and we observed similar results (pooled OR 1.02 \[1.01--1.04\] with each point of the genotype score; *P* = 0.01).

###### 

Association between the HDL cholesterol genotype score and risk for type 2 diabetes
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Triglyceride genotype score and type 2 diabetes. {#s12}
------------------------------------------------

The ORs for type 2 diabetes were both 1.02 (95% CI 0.99--1.05) with each point of the triglyceride genotype score in women and men, and the pooled OR was 1.02 (1.00--1.04), after adjustment for age and BMI ([Table 4](#T4){ref-type="table"}). The ORs for type 2 diabetes increased across the quartiles of the triglyceride genotype score (*P* = 0.007 for trend). Participants in the highest quartile of the triglyceride genotype score had an OR of 1.19 (1.00--1.40) compared with those in the lowest quartile. Multivariate adjustment did not change the associations. Linear relation analysis also indicated that the triglyceride genotype score showed a linear relationship with increasing type 2 diabetes risk ([Fig. 2*C*](#F2){ref-type="fig"}). In sensitivity analysis, we excluded four SNPs (*GALNT2* rs1321257, *ZNF664* rs12310367, *LIPC* rs261342, and *PLTP* rs4810479) that had the largest effects on LDL or HDL cholesterol levels from the calculation of the triglyceride genotype score, and we observed similar results (pooled OR 1.03 \[1.01--1.05\] with each point of the genotype score; *P* = 0.015).

###### 

Association between the triglyceride genotype score and risk for type 2 diabetes
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DISCUSSION {#s13}
==========

In two well-established prospective, nested case-control studies of U.S. women and men, we found that the genetic predisposition to dyslipidemia of low HDL cholesterol or high triglyceride levels significantly increases type 2 diabetes risk. In consideration of the fact that the individual SNPs may have quite moderate effects on type 2 diabetes risk, we examined the collective contribution of the multiple genetic variants by computing three lipid genotype scores, which emphasized the overall genetic susceptibility to dyslipidemia of high LDL cholesterol, low HDL cholesterol, or high triglycerides. As greater genetic variation was explained by multiple variants, the genetic predisposition might be estimated more accurately by using this approach. Each additional risk allele in the genotype scores of HDL cholesterol or triglycerides only was associated with an \~2--3% increased risk for type 2 diabetes. By accumulation, participants with an HDL cholesterol genotype score in the highest quartile had an \~40% greater risk of developing type 2 diabetes than those in the lowest quartile.

Consistent with the previously reported additive effects of multiple genetic variants on plasma lipid levels ([@B9]), we confirmed that the genotype scores summarizing the number of LDL cholesterol-- or triglyceride-raising alleles or HDL cholesterol--lowering alleles were associated with higher LDL cholesterol and triglyceride levels and lower HDL cholesterol levels, respectively, in diabetic men and women. Our data indicated that the genotype scores for low HDL cholesterol or high triglycerides were associated with elevated type 2 diabetes risk, whereas the LDL cholesterol genotype score was not related to diabetes risk. These findings are largely in line with previous observations from the prospective studies showing that low HDL cholesterol and high triglyceride levels, but not high LDL cholesterol levels, significantly predicted the risk of type 2 diabetes ([@B2]--[@B7]). Because genetic variants are randomly assigned and generally uncorrelated with environmental factors, the observed genetic associations should be unaffected by confounding factors and also free of the inverse effect of type 2 diabetes. Thus, our results support potentially causal roles of HDL cholesterol and triglycerides in type 2 diabetes. However, we could not exclude the possibility that the genotype scores might be related to other unknown variables in the causal pathway. Our data are different from a previous study that did not find the significant association between a triglyceride genotype score and type 2 diabetes risk ([@B8]). Of note, the previous study included fewer loci (which only accounted for 3--5% of the variation in circulation triglycerides \[[@B8]\]) than our study. The current triglyceride genotype score included more loci, which jointly explained \~10% of the variation of plasma triglycerides ([@B9]).

There are several lines of evidence supporting the probably causal relationship between low HDL cholesterol/high triglyceride levels and type 2 diabetes risk. Recent data indicated that HDL may influence β-cell function by its abilities of cholesterol efflux, antioxidation, anti-inflammation, and antiapoptosis ([@B26]), and accumulation of triglycerides ectopically in other tissues than adipose may impair insulin signaling as well as insulin secretion ([@B27]). Findings from previous prospective studies in large populations from different ethnical groups have shown that plasma HDL cholesterol and triglyceride levels are independent predictors of future type 2 diabetes ([@B2]--[@B7]). For instance, a previous study comprising \>14,000 participants found that the risk of new-onset diabetes decreased by 28% and increased by 12% per mmol/L increase in baseline HDL cholesterol and triglyceride levels, respectively ([@B5]). The observed associations between the genetic predisposition to low HDL cholesterol or high triglycerides and elevated type 2 diabetes risk in the current study provide further evidence for the true association, because they are unlikely to be the results of confounding factors. Moreover, importantly, data from some clinical trials have shown that bezafibrate, a drug used to treat dyslipidemia by raising HDL and lowering triglycerides, could improve insulin resistance ([@B28]) and lower the hazard for incident diabetes ([@B29],[@B30]). Taken together, these findings support that contention that dyslipidemia of low HDL cholesterol/high triglycerides plays a causal role in the development of type 2 diabetes, which suggests the potential importance of therapeutic implications of dyslipidemia, either pharmacologically or through lifestyle intervention, in preventing type 2 diabetes.

The major strengths of our study include the prospective study design, high-quality genotype data, and minimal population stratification ([@B13]). We acknowledge that plasma lipids were not measured in control participants. Although our lipid genotype scores captured the combined information from most of the established genetic variants for blood lipids, these variants only explained \~10% variation of each lipid trait ([@B9]). This may explain the observed moderate effect of the lipid genotype scores on type 2 diabetes risk. There were several overlapped SNPs included in these three lipid genotype score, because these SNPs have been associated with more than one lipid trait ([@B9]). However, in our sensitivity analyses, when the SNPs that had the largest effects on other two lipid traits were excluded from the calculation of the genotype score, we observed similar results. In addition, our study is restricted to white subjects, and whether the genotype scores of HDL cholesterol and triglycerides are significantly associated with type 2 diabetes in other ethnic groups remains to be investigated.

In conclusion, we found that the genetic predisposition to low HDL cholesterol or high triglycerides, estimated by the lipid genotype scores, were associated with an increased risk of type 2 diabetes among women and men from two prospective cohorts. Our findings support a potentially causal relationship between low HDL cholesterol or high triglyceride levels and type 2 diabetes.
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